注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Cingulate Inc是一家临床阶段的生物制药公司。该公司专注于利用精确定时释放(PTR)药物输送平台技术开发,制造和商业化药品,以创建剂量计划和药物释放曲线,改善患有多种常见疾病的患者的生活。该公司专注于注意力缺陷/多动障碍(ADHD)的治疗。该公司正在开发两种主要候选产品,如CTx-1301(右哌甲酯)和CTx-1302(右旋安非他明)。其CTx-1301和CTx-1302候选药物均含有三种释放的活性药物成分,组合成一种小片剂型。其CTx-1301和CTx-1302正在开发用于治疗ADHD的三个核心患者部分:儿童(6-12岁),青少年(13-17岁)和成人(18岁以上)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Brian D. Barash | - | - | Member of Scientific Advisory Board |
Andrew J. Cutler | - | - | Member of Scientific Advisory Board |
John S. Markowitz | - | - | Member of Scientific Advisory Board |
Alice Mao | - | - | Member of Scientific Advisory Board |
Ann Childress | - | - | Member of Scientific Advisory Board |
Sharon B. Wigal | - | - | Member of Scientific Advisory Board |
Peter J. Werth | 84 | 2018 | Director |
Declan Quinn | - | - | Member of Scientific Advisory Board |
Ignacio Herman Valdes | - | - | Member of Scientific Advisory Board |
Dinohra Munoz-Silva | - | - | Member of Scientific Advisory Board |
Jeffrey S. Ervin | 46 | 2024 | Director |
Bryan Jay Lawrence | 58 | 2024 | Director |
Jeffrey Newcorn | - | - | Member of Scientific Advisory Board |
Laurence L. Greenhill | - | - | Member of Scientific Advisory Board |
John A. Roberts | 65 | 2024 | Independent Director |
Shane J. Schaffer | 49 | 2012 | CEO & Chairman of the Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核